Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsBCBSNM Drug List Coverage & Prior Auth Update | Op…
    Ask Trek AI about this page

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    CurrentBlue Cross Blue Shield - New MexicoPolicy N/A

    2025 Drug List (Pharmacy Benefit) — Formulary and Utilization Management

    Customize your policy alerts

    Sign up for all Blue Cross Blue Shield - New Mexico policy alerts

    Know when Blue Cross Blue Shield - New Mexico releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This document governs the pharmacy drug list for Blue Cross and Blue Shield of New Mexico members, describing covered drugs, tier placement, specialty drug handling, and benefit processes such as prior authorization, step therapy, quantity limits, and exception processes for members and providers.

    Policy Summary
    PayerBlue Cross Blue Shield - New Mexico
    Policy2025 Drug List (Pharmacy Benefit) — Formulary and Utilization Management
    Policy CodePolicy N/A
    Change TypeAnnual drug list update (no material changes)
    Effective DateOct 1, 2025
    Next Review DateN/A
    Key ActionObtain prior authorization for drugs marked 'PA' and submit required clinical documentation to support PA and any quantity-limit exceptions.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    ~120Drug entries (excerpt)
    manyEntries with PA/QL/SP flags
    AccredoSpecialty pharmacy partner
    30/90Typical day supply
    NumerousSpecialty/antineoplastic agents

    Coverage and Formulary Controls

    General coverage

    Coverage is provided for drugs listed on the Drug List and is subject to plan-specific rules and special requirements noted in the list.

    General conditions for drug coverage: Drug is listed on the BCBSNM Drug List; drug coverage follows the member's benefit plan; drugs not shown on the Drug List are not covered.

    Members and providers should consult MyPrime.com or bcbsnm.com or call the number on the ID card for the most current Drug List and benefit-specific details.

    General formulary coverage conditions

    Covered when plan rules for formulary tier and utilization controls are met

    Formulary tier and utilization controls: Drug is assigned a formulary Drug Tier (e.g., Preferred Generic, Non‑Preferred Brand, Preferred Specialty). Coverage is subject to the entry's Requirements/Limits; if 'PA' is shown, prior authorization must be obtained; if 'QL' is shown, quantity limits must not be exceeded; if 'ST' is shown, step therapy requirements apply.

    See the Drug List line item for the product-specific Tier and Requirements/Limits.

    Policy Summary
    PayerBlue Cross Blue Shield - New Mexico
    Policy2025 Drug List (Pharmacy Benefit) — Formulary and Utilization Management
    Policy CodePolicy N/A
    Change TypeAnnual drug list update (no material changes)
    Effective DateOct 1, 2025
    Next Review DateN/A
    Key ActionObtain prior authorization for drugs marked 'PA' and submit required clinical documentation to support PA and any quantity-limit exceptions.
    SourceLink
    On This Page
    Coverage and Formulary ControlsFormulary Listings & Coding DetailsAuthorization, Documentation, Step Therapy — Provider ResponsibilitiesInitiation Controls and RequirementsStep Therapy Rules and Affected ProductsQuantity Limits (QL) — Examples and Per-Product CapsDispensing Channels and Medical Benefit ConsiderationsAbbreviations and Tier ConventionsPolicy BackgroundPolicy Revision History

    Coverage flags and controls (product-level)

    Products are listed with coverage-related flags; where 'PA' or 'QL' appear, coverage is contingent on meeting prior authorization or quantity-limit policies

    Coverage flags on product entries: Individual products include Requirements/Limits fields such as PA (prior authorization), QL (quantity limit), SP (specialty pharmacy), AC (administrative coverage) and ST (step therapy). Coverage for that product requires adherence to the listed flags.

    The document lists many examples where PA/QL/SP are present; specific clinical PA or ST criteria are provided through the payer's prior authorization/step-therapy processes rather than on the line item.

    Formulary administrative coverage conditions

    Coverage stance is per drug entry with conditions such as PA, QL, and SP as specified

    Administrative coverage conditions: Each formulary line shows a Drug Tier and may include Requirements/Limits such as PA, QL, SP and AC. When present these administrative controls condition coverage for the product as listed.

    No full clinical medical-necessity algorithms are contained in these excerpts; product-specific PA criteria and specialty routing are managed via the payer's authorization processes.

    Formulary coverage controls

    Coverage and utilization controls are specified per product; common controls include Prior Authorization (PA), Quantity Limits (QL) with interval, and Specialty Pharmacy (SP).

    Per-product control examples - prednisolone: Prednisolone sodium phosphate oral solution 10 mg/5 mL — Requirements/Limits = PA, QL (900 mLs/30 days).QL 900 mLs/30 days

    See prednisolone entries for exact formulation-specific QL values.

    Per-product control examples - prednisone (Rayos): Rayos (prednisone delayed release) — Requirements/Limits = QL (30 tablets/30 days).QL 30 tablets/30 days

    Rayos is listed with QL as shown on the Drug List.

    Per-product control examples - methyltestosterone/testosterone: Methyltestosterone — Requirements/Limits = PA, QL (600 tablets/30 days); multiple testosterone formulations also show PA and product-specific QLs (e.g., packets, pumps, mLs).PA plus QL as listed

    See testosterone and methyltestosterone line items for formulation-specific QLs and PA flags.

    Product-level coverage summary (selected examples)

    Coverage and utilization management applies per product as listed below (examples from these chunks):

    PA required at initiation for selected antidiabetics: Certain antidiabetic agents and formulations are denoted with PA at initiation (examples include metformin oral solution Riomet, MOUNJARO, OZEMPIC, TRULICITY).

    PA designation on the Drug List indicates prior authorization is required per plan procedures before coverage.

    Quantity-limited products: Products with 'QL' include explicit maximum quantities per time period (examples: JANUMET XR QL 60 tablets/30 days; many insulin products QL 100 mLs/30 days; MOUNJARO QL 4 pens/28 or 180 days depending on strength).See product line for QL value

    Claims exceeding QL require prior authorization or member may be responsible for cost beyond coverage limits.

    Coverage for medications is determined by the Drug List and is subject to the member's specific benefit rules and any special requirements shown on the formulary. In general, coverage applies to drugs that are listed on the BCBSNM Drug List and that meet plan rules; many entries include administrative controls such as Prior Authorization (PA), Quantity Limits (QL) and Specialty Pharmacy (SP) routing which must be satisfied for coverage to be approved. Typical dispensing expectations are a 30‑day supply for most prescriptions and up to a 90‑day supply for maintenance medications where the benefit allows. [[chunk 9]]

    The Drug List presents per‑product formulary placement (Drug Tier) and line‑level requirements. When an item is marked with PA the prescriber must submit a prior authorization request and obtain approval before the payer will cover the medication. Entries that include QL specify the maximum permitted quantity and time window (for example, many antiretrovirals and DAAs show QL (30 tablets/30 days)). Products marked SP must be dispensed through specialty pharmacy channels as indicated. Coverage is therefore conditional on meeting those per‑product requirements. [[chunk 36]][[chunk 37]][[chunk 72]]

    Examples from the listing illustrate how utilization management is applied at the product level. Selected antiviral and anti‑infective products show QL limits (e.g., BIKTARVY QL (30 tablets/30 days); linezolid suspension QL (600 mL/180 days)). Many oncology and specialty agents are designated PA, QL, SP (for example, Zytiga/abiraterone PA, QL (60 tablets/30 days), SP; alectinib PA, QL (240 capsules/30 days), SP). Biologic and specialty injectables (e.g., benralizumab, mepolizumab) are shown with PA and product‑specific QLs and are managed via specialty pharmacy where indicated. Providers should follow the line‑item Requirements/Limits for each product. [[chunk 54]][[chunk 72]][[chunk 216]]

    The Drug List also identifies items that are not covered under typical pharmacy benefits: repackaged medications, non–FDA‑approved drugs, certain compounded medications and some prescription products that have available over‑the‑counter equivalents may be excluded from coverage. Where an entry shows administrative flags only (PA/QL/SP) the document excerpt does not provide full clinical medical‑necessity criteria — those are managed through the payer's PA processes and documentation requirements. Providers should consult plan materials or the PA process to determine the specific clinical documentation required for approval. [[chunk 9]][[chunk 72]][[chunk 108]]

    This excerpt of the Drug List does not present explicit exclusion lists naming individual agents that are categorically not covered; instead coverage limitations are expressed by omission from the list or via per‑product administrative designations. For example, formulary rows contain Drug Tier and Requirements/Limits values (PA, QL, SP) rather than standalone exclusion statements. Where a product is absent from the Drug List it is not covered under the pharmacy benefit. Refer to the plan's benefit materials for any additional product or category exclusions (e.g., certain cosmetic or age‑restricted uses). [[chunk 36]][[chunk 37]][[chunk 9]]

    Because many entries in this excerpt focus on formulary placement and utilization controls rather than explicit exclusion language, providers should assume that lack of a line‑item on the Drug List or failure to meet listed Requirements/Limits (for example, missing PA or exceeding QL) can result in a coverage denial. Exception and appeals processes are available through the telephone number on the member ID card or the plan's benefit guidance. [[chunk 234]][[chunk 72]]

    The document excerpt does not include explicit clinical exclusion criteria tied to medical conditions (for example, diagnoses, prior‑therapy failures or contraindications) for the products shown. Instead, coverage is signaled by inclusion on the Drug List with any administrative controls specified on the same line. Where clinical criteria are required to support a PA, those criteria and the required documentation are managed through the payer's authorization process rather than in the line‑item entries in this excerpt. [[chunk 54]][[chunk 72]][[chunk 163]]

    Examples in the listing show how utilization management is applied without listing clinical exclusions: corticosteroid and androgen products include QLs or PA (e.g., prednisolone oral solution QL (900 mL/30 days); Rayos QL (30 tablets/30 days); methyltestosterone PA, QL (600 tablets/30 days)), but the excerpt does not state specific clinical conditions that would exclude coverage. For specialty metabolic and endocrine therapies (e.g., SOMAVERT, TYMLOS, CRENESSITY) the entries show PA, QL and often SP designations; the clinical justification required for PA must be provided when submitting authorization. [[chunk 108]][[chunk 111]][[chunk 152]]

    The excerpt emphasizes administrative utilization controls as the primary mechanism governing coverage for listed products: Prior Authorization (PA) is required where noted, Quantity Limits (QL) define permitted dispensing amounts and windows, Specialty Pharmacy (SP) flags require dispensing through specialty channels, and Step Therapy (ST) appears on selected products. Claims that lack required PA or that exceed QL are at risk for denial. Providers must follow the Requirements/Limits column and the payer's PA documentation instructions. [[chunk 72]][[chunk 90]][[chunk 163]]

    Many high‑cost, specialty and oncology agents in the listing show combined controls (for example, PA + QL + SP). Representative examples include: abiraterone (Zytiga) — PA, QL (60 tablets/30 days), SP; REPATHA products (evolocumab) — PA with presentation‑specific QLs (e.g., 6 syringes/28 days, 2 cartridges/30 days, 6 pens/28 days); FUROSCIX — PA, QL (8 kits/180 days); enalapril oral solution (Epaned) — PA, QL (1200 mL/30 days). Providers should attach clinical justification per the PA process when requesting exceptions or quantities above the stated QL. [[chunk 72]][[chunk 197]][[chunk 188]][[chunk 182]]

    Where a line‑item shows only administrative controls (PA/QL/SP) the document excerpt does not include the underlying clinical necessity rules; those are enforced through the payer's authorization review and supporting documentation requirements. For operational questions or to initiate exception/PA requests, use the contact information on the member ID card or the plan's provider resources. [[chunk 93]][[chunk 111]][[chunk 194]]

    Formulary Listings & Coding Details

    Formulary drug entries (partial)mixed
    APRETUDEcabotegravir im extended release susp 600 mg/3ml
    APTIVUStipranavir cap 250 mg
    BARACLUDEentecavir oral soln 0.05 mg/ml
    BIKTARVYbictegravir-emtricitabine-tenofovir af tab 30-120-15 mg, 50-200-25 mg
    CIMDUOlamivudine-tenofovir disoproxil fumarate tab 300-300 mg
    COMPLERAemtricitabine-rilpivirine-tenofovir df tab 200-25-300 mg
    Hepatitis C DAAs with PA/QL/SP flagsmixedCovered
    EPCLUSAsofosbuvir-velpatasvir tab/pellet pack
    HARVONIledipasvir-sofosbuvir tab/pellet pack
    MAVYRETglecaprevir-pibrentasvir tab/pellet pack
    SOVALDIsofosbuvir tab/pellet pack
    VOSEVIsofosbuvir-velpatasvir-voxilaprevir tab
    Antimalarial/antiparasitic entriesmixedCovered
    ARAKODAtafenoquine succinate tab 100 mg
    COARTEMartemether-lumefantrine tab 20-120 mg
    SOLOSECsecnidazole granules packet 2 gm
    Formulary product strengths and quantity limitsmixed
    600 mglinezolid tablet strength listed (600 mg)
    100 mg/5mllinezolid suspension strength listed (100 mg/5 ml)
    120 capsules/30 daysvancomycin QL
    9 tablets/30 daysrifaximin 200 mg QL
    60 tablets/30 daysrifaximin 550 mg QL
    QL (56 tablets/180 days)linezolid 600 mg tablet QL
    QL (600 mls/180 days)linezolid suspension QL
    QL (6 tablets/180 days)tedizolid (Sivextro) QL
    QL (120 tablets/30 days)abiraterone acetate QL
    QL (60 tablets/30 days)akeega QL
    Listed drugs and strength entries (no billing codes provided in this excerpt)mixed
    abiraterone acetate tab 500 mgZytiga — Drug Tier = np; Requirements/Limits = PA, QL (60 tablets/30 days), SP
    ACTIMMUNE - interferon gamma-1b inj 100 mcg/0.5mlRequirements/Limits = SP
    AKEEGA - niraparib tosylate-abiraterone acetate tab 50-500 mg, 100-500 mgDrug Tier = NP; Requirements/Limits = PA, QL (60 tablets/30 days), SP
    ALECENSA - alectinib hcl cap 150 mgDrug Tier = P; Requirements/Limits = PA, QL (240 capsules/30 days), SP
    ALUNBRIG - brigatinib various strengthsDrug Tier = P; Requirements/Limits vary by strength including PA and QL
    AUGTYRO - repotrectinib cap 40 mg; 160 mgDrug Tier = NP; Requirements/Limits = PA, QL (30 or 60 capsules/30 days), SP
    AYVAKIT - avapritinib tab 25-300 mgDrug Tier = P; Requirements/Limits = PA, QL (30 tablets/30 days), SP
    BALVERSA - erdafitinib tab 3-5 mgDrug Tier = NP; Requirements/Limits = PA with QL varying by strength, SP
    BESREMI - ropeginterferon alfa-2b-njft prefilled syr 500 mcg/mlDrug Tier = P; Requirements/Limits = PA, QL (2 syringes/28 days), SP
    bexarotene cap 75 mgTargretin — Drug Tier = np; Requirements/Limits = PA, SP
    1–10 of 83
    1/9
    Formulary entries (no billing codes)mixed
    N/ADocument is a formulary listing; no CPT/HCPCS/ICD-10 billing codes are provided in these chunks.
    Formulary drug entries (partial)mixed
    medroxyprogesterone acetate tab 2.5 mg, 5 mg, 10 mgProvera — listed with Drug Tier entries
    megestrol acetate susp 625 mg/5mlMegestrol acetate suspension
    norethindrone acetate tab 5 mgAygestin
    progesterone cap 100 mg, 200 mgPrometrium
    metformin hcl oral soln 500 mg/5ml (Riomet)Riomet (PA, QL 780 mls/30 days)
    MOUNJARO - tirzepatide soln auto-injector (various strengths)PA, QL (4 pens/180 days or 4 pens/28 days depending on strength)
    OZEMPIC - semaglutide soln pen-inj (various strengths)PA, QL (1 pen/28 days or 3 ml/28 days depending on strength)
    JANUMET / JANUMET XR - sitagliptin-metformin (various strengths)P, QL (30 or 60 tablets/30 days depending on formulation)
    FIASP / HUMALOG / NOVOLOG / LYUMJEV (insulins)Various insulin products with QL (100 mls/30 days) for many formulations
    GLUCAGON emergency products (BAQSIMI, GVOKE, glucagon inj kits)Rescue glucagon products listed with Drug Tier P and assorted Requirements/Limits
    Formulary product entries (selected examples)mixed
    70/30 RELIONinsulin aspart prot & aspart (human) inj 100 unit/ml (70-30) - QL (100 mls/30 days)
    INSULIN GLARGINE-YFGNinsulin glargine-yfgn soln pen-injector 100 unit/ml - QL (100 mls/30 days)
    SEMGLEEinsulin glargine-yfgn soln pen-injector 100 unit/ml - QL (100 mls/30 days)
    TOUJEO MAX SOLOSTARinsulin glargine soln pen-injector 300 unit/ml - QL (100 mls/30 days)
    TRESIBAinsulin degludec inj 100 unit/ml - QL (100 mls/30 days)
    SYNTHROID / levothyroxinelevothyroxine sodium tablets various strengths - Drug Tier = P
    TIROSINT / TIROSINT-SOLlevothyroxine sodium capsules and oral solution - Drug Tier = NP
    ACTHARcorticotropin inj gel 80 unit/ml - Requirements/Limits = PA, SP
    CRENESSITYcrinecerfont cap and soln - Requirements/Limits = PA, QL (60 caps/30 days or 120 mls/30 days), SP
    SOMAVERTpegvisomant for injection various strengths - Requirements/Limits = PA, QL (30 vials/30 days), SP
    Formulary items (no CPT/HCPCS/ICD codes provided)mixed
    No codes listed
    Products with PA/QL/SP notedmixed
    FUROSCIX - furosemide subcutaneous cartridge kit 80 mg/10mlPA, QL (8 kits/180 days)
    enalapril oral soln 1 mg/ml (Epaned)PA, QL (1200 mL/30 days)
    QBRELIS - lisinopril oral soln 1 mg/mlPA, QL (2400 mL/30 days)
    colesevelam hcl packet 3.75 gm (Welchol)PA, QL (30 packets/30 days)
    NEXLETOL - bempedoic acid tab 180 mgPA, QL (30 tablets/30 days)
    REPATHA - evolocumab 140 mg/mLPA, QL (6 syringes/28 days)
    REPATHA PUSHTRONEX - evolocumab 420 mg cartridgePA, QL (2 cartridges/30 days)
    REPATHA SURECLICK - evolocumab 140 mg/mL auto-injectorPA, QL (6 pens/28 days)
    ADEMPAS - riociguat tab (various strengths)PA, QL (90 tablets/30 days), SP
    Formulary drug list (cardiovascular and related)mixed
    multiple generic and brand cardiovascular agentsIncludes ACE inhibitors, ARBs, beta-blockers, diuretics, vasopressors, antihyperlipidemics, and miscellaneous cardiac agents with dose forms and tiers as listed
    Drug list (no procedural codes)mixed
    noneThis segment contains no CPT/HCPCS/ICD-10 codes; it lists drug names, strengths, tiers, and requirements/limits.
    Example Antiemeticsmixed
    ANZEMETdolasetron mesylate tab 50 mg
    aprepitant capsule therapy pack 80 & 125 mg (Emend tripack)Requirements/Limits = QL (3 packs/30 days)
    aprepitant capsule 40 mgRequirements/Limits = QL (2 capsules/30 days)
    aprepitant capsule 80 mg (Emend)Requirements/Limits = QL (6 capsules/30 days)
    aprepitant capsule 125 mgRequirements/Limits = QL (3 capsules/30 days)
    Digestive Aidsmixed
    CREON - pancrelipase dr cap (multiple strengths)Drug Tier = P
    SUCRAID - sacrosidase soln 8500 unit/mlRequirements/Limits = PA, QL (300 mls/30 days), SP
    ZENPEP - pancrelipase dr cap (multiple strengths)Drug Tier = P
    Selected Biologics / Specialtymixed
    CIMZIAcertolizumab pegol prefilled syringe kit 200 mg/ml — PA, QL (2 kits/28 days), SP
    ENTYVIO PENvedolizumab soln auto-injector 108 mg/0.68ml — PA, QL (2 pens/28 days), SP
    GATTEXteduglutide for inj kit 5 mg — PA, SP
    Immunomodulators (examples)mixed
    SKYRIZIrisankizumab-rzaa cartridge 180 mg/1.2ml — PA, QL (1 cartridge/56 days), SP
    TREMFYAguselkumab prefilled syringe 200 mg/2ml — PA, QL (1 syringe/28 days), SP
    Genitourinary / Vaginal productsmixed
    GEMTESAvibegron tab 75 mg
    MYRBETRIQmirabegron tab er 24 hr 25 mg, 50 mg
    ENDOMETRINprogesterone vaginal insert 100 mg
    Typical day supply
    Typical day supply30-day supply typical; up to 90-day supply for maintenance medications
    Maintenance medication definition (examples)Medications taken on an ongoing basis for conditions such as hypertension, diabetes, or high cholesterol
    ExceptionsSome plans may exclude certain categories (e.g., erectile dysfunction, weight loss) or restrict by age or cosmetic use; refer to member plan materials
    Common QL examples
    Common QL examplesExamples include 30 tablets/30 days; 60 tablets/30 days; 90 tablets/30 days
    Antiretroviral QLsMultiple antiretrovirals (e.g., BIKTARVY, COMPLERA, DOVATO) listed with QL (commonly 30 tablets/30 days)
    Formulary noteQuantity limits are specified per product line in the Drug List and must be followed unless an exception is approved
    Quantity limits
    Quantity limits (illustrative)Examples include 120 capsules/30 days; 60 tablets/30 days; 9 tablets/30 days; 600 mL/180 days
    Antibiotic QLsExamples: vancomycin HCl capsules QL 120 capsules/30 days; rifaximin 200 mg QL 9 tablets/30 days; rifaximin 550 mg QL 60 tablets/30 days
    Oncology/specialty QLsMany oncology agents show specific QLs per strength (e.g., abiraterone 60 tablets/30 days) and are managed as listed
    Common quantity limits
    Common quantity limit patternsExamples: 30 tablets/30 days; 60 tablets/30 days; 120 tablets/30 days; 84–168 units/28 days
    Capsule/pack QLsSome agents list multi-pack or capsule ranges (e.g., AUGTYRO QL 30 or 60 capsules/30 days depending on strength)
    Specialty unit QLsCertain specialty therapies list unit-based QLs (e.g., 84–168 units/28 days for specified formulations)
    Prednisolone oral solution QL
    Prednisolone oral solution QL900 mls/30 days
    Other prednisolone/prednisone entriesAdditional prednisolone/prednisone formulations show varying QLs (e.g., 450 mls/30 days for 20 mg/5 ml soln; Rayos QL shown in other entries)
    Per-product QLs must be observedClaims exceeding listed QLs may be denied without supporting authorization/documentation
    Rayos (delayed-release prednisone) and related QLs
    Rayos (delayed-release prednisone) QL30 tablets/30 days
    Methyltestosterone QL600 tablets/30 days
    Testosterone gel QL examplesExamples include 30 packets/30 days; 2 pumps/30 days; 150 grams/30 days; 300 grams/30 days

    Authorization, Documentation, Step Therapy — Provider Responsibilities

    Prior Authorization

    Obtain prior authorization when 'PA' is shown

    Some drugs listed on the Drug List require prior authorization before the plan will cover them; such medications are generally noted with 'PA' in the Special Requirements column and the prescriber must submit a prior authorization request and receive approval prior to dispensing for coverage to apply.

    • PA is indicated next to medications when prior authorization is commonly required.
    • Provider must submit a prior authorization request and obtain approval before the medication may be covered.
    Prior Authorization

    PA required for listed hepatitis C/antiviral agents

    Multiple hepatitis C and other antiviral agents (examples: EPCLUSA, HARVONI, MAVYRET, SOVALDI, VOSEVI) are listed with 'PA' (and often 'QL' and 'SP'); providers must obtain prior authorization for these products per the formulary entry before coverage is available.

    • EPCLUSA, HARVONI, MAVYRET, SOVALDI, and VOSEVI entries include Requirements/Limits = PA (and QL/SP as noted).
    • Prior authorization must be obtained per the Special Requirements for these antiviral regimens.
    Prior Authorization

    PA required for listed specialty oncology/targeted agents

    Many specialty oncology and targeted therapy agents in the formulary are marked with Requirements/Limits = PA (and frequently SP and QL); prescribers must obtain prior authorization and follow specialty pharmacy routing where indicated prior to coverage.

    • Examples include abiraterone (Zytiga), ALECENSA, ALUNBRIG, AUGTYRO and many others with PA, QL, and SP flags.
    • Specialty (SP) designation requires dispensing via the specialty channel when listed.
    Prior Authorization

    Obtain PA for drugs marked 'PA' to avoid denial

    Numerous drugs across the formulary excerpt are designated 'PA' — prescriptions for drugs marked 'Requirements/Limits = PA' may be denied if prior authorization is not obtained before dispensing.

    • Providers must obtain PA for products with 'PA' noted to avoid claim denial.
    • Many PA-marked products also include quantity limits (QL) that must be observed.
    Step Therapy

    Follow step therapy (ST) when indicated or submit exception

    When a product is subject to step therapy ('ST') the plan may require trying a preferred, first-line medication before covering the requested drug; prescribers can request a step therapy exception if the preferred option is not appropriate.

    • Step Therapy is noted with 'ST' next to medications when required.
    • Providers may submit a step therapy exception request per the plan's exception process.
    Prior Authorization

    Specialty (SP) + PA entries require specialty routing and PA

    Some high-cost hepatitis C and antiviral therapies and select other specialty products are marked with 'SP' and 'PA', which indicates they require specialty pharmacy processing and prior authorization; this combination may imply specialty pathways or prior-step management before coverage.

    • Entries such as EPCLUSA, HARVONI, SOVALDI show PA and SP together.
    • Provider must follow specialty pharmacy routing and obtain PA as listed.
    Note

    No explicit step therapy sequences provided in this excerpt

    This excerpt does not specify explicit step-by-step step therapy sequences; the formulary primarily uses flags (PA, QL, SP) to indicate controls rather than detailed ST algorithms.

    • No explicit step therapy sequences are described in these chunks — only PA, QL, and SP designations are shown.
    • Refer to the full policy or benefit materials for any detailed ST algorithms.
    Documentation Required

    Use the ID‑card phone number to request exceptions (standard & expedited)

    A prescriber or member may request a drug list or step therapy exception by calling the phone number on the member's ID card; BCBSNM will notify the requester of the decision within three business days (or within 24 hours for expedited requests when life/health is jeopardized).

    • Standard exception decisions communicated within three business days after receipt.
    • Expedited reviews are available and decided within 24 calendar hours for urgent situations.
    Documentation Required

    Submit PA and specialty pharmacy documentation when 'PA' or 'SP' listed

    When a formulary entry includes 'PA' or 'SP' the provider must obtain prior authorization and/or route the prescription through the specialty pharmacy as required; supporting clinical documentation must be submitted to justify the PA and any requested quantity above stated QLs.

    • PA and SP designations require adherence to the plan's authorization and specialty pharmacy processes.
    • Prescribers must supply clinical documentation to support PA requests and quantity justifications for QL exceedances.
    Note

    Observe the formulary requirement type (PA, QL, AC, SP) shown

    Formulary entries use specific requirement types: QL (quantity limits), PA (prior authorization), AC (administrative coverage/access control), and SP (specialty pharmacy); providers must follow the type of control shown on the product line.

    • QL indicates maximum quantity allowed per the stated time period (e.g., 30 tablets/30 days).
    • AC, PA, and SP denote other administrative or specialty routing controls that must be followed.
    Documentation Required

    Provide required documentation for PA and QL

    Prescribers and pharmacies must submit prior authorization documentation for drugs listed with 'Requirements/Limits = PA' and must adhere to the product's quantity limits (QL) and specialty pharmacy (SP) routing where specified to avoid claim denials.

    • Documentation should support the medical necessity and any requested quantity exceeding the QL.
    • Failure to submit PA and required documentation may result in denial of coverage.
    Note
    Note
    Note
    Note
    Note
    Note

    Initiation Controls and Requirements

    Initial therapy requirements (partial)

    When initiating therapy for covered antidiabetic agents, the following apply (examples):

    PA at initiation for selected antidiabetics: Certain GLP‑1/GIP‑GLP‑1 and other branded antidiabetics (examples: MOUNJARO, OZEMPIC, TRULICITY) are listed with 'PA' at initiation and may also show QL limits for initial dispensing.

    PA and QL flags are printed on the product lines; see formulary entries for the required PA process.

    Initiation controls

    At therapy initiation, apply ALL applicable utilization controls shown on the product line:

    Initiation utilization controls: If a product line shows 'PA', the provider must obtain prior authorization prior to the initial dispense; QL values apply from the first fill and quantities above the QL require prior approval; products marked 'SP' must be dispensed via specialty pharmacy for initial and subsequent fills.

    Specific clinical PA criteria are not included in this excerpt; refer to the payer's PA documentation process.

    Initial therapy requirements (per product flags)

    Initial coverage for listed specialty/high‑cost agents is contingent on the product flags below (examples):

    Per‑product initiation flags: Products such as phenylbutyrate (Buphenyl) are marked PA + SP; SOMAVERT requires PA + QL (30 vials/30 days) + SP; STRENSIQ requires PA + SP. When these flags are present, prior authorization and specialty routing are required before initial coverage is approved.

    See specific product lines for exact QL values and specialty handling.

    Initial therapy controls (partial)

    Initial therapy coverage controls for specialty/biologic agents (examples):

    Biologic/specialty initiation controls: Many biologic and specialty therapies (for example FASENRA PEN, NUCALA, TEZSPIRE, TRIKAFTA) are listed with 'PA' and product‑specific QLs; prior authorization is required prior to the first dispense and specialty pharmacy handling (SP) may be required.

    Refer to product listings for the QL intervals (e.g., 1 pen/28 days for FASENRA).

    Step Therapy Rules and Affected Products

    RequirementNotes / action
    Try preferred first-line medication(s) before covering the requested drug when ST is indicated
    Step Therapy (ST) means a member must try a first-line, cost-effective medication prior to coverage of the requested agent; if the preferred first-line drug is not appropriate, the prescriber may submit a step therapy exception request per the plan's exception process.
    Formulary designationImplication
    Hepatitis C DAAs (e.g., EPCLUSA, SOVALDI) marked PA and SP
    PA indicates prior authorization is required and SP indicates specialty pharmacy routing — these flags imply specialty handling and utilization controls that may include step or specialty management prior to coverage.
    ControlEffect on coverage / provider action
    PA required for many specialty/antineoplastic agents
    Products listing 'Requirements/Limits = PA' must have prior authorization approved before coverage will be provided; providers must follow the payer's PA process and submit supporting clinical documentation.
    Contraceptive flagInterpretation
    Contraceptives listed with AC and/or PA (examples: ANNOVERA, various combined oral contraceptives)
    AC denotes administrative/access controls and PA denotes prior authorization; the listings show these controls are applied but explicit step sequences are not provided in these chunks — providers must follow AC/PA procedures as applicable.
    Agent / classFormulary flags
    Selected branded GLP‑1/GIP‑GLP‑1 agents (e.g., MOUNJARO, OZEMPIC, TRULICITY)
    These products are listed with 'PA' (prior authorization) and QL entries in the formulary — prior authorization may be required before accessing these preferred branded agents.
    ProductFlag
    KERENDIA (finerenone)
    Listed with 'ST' indicating step therapy applies; specific step requirements are not provided in these chunks.
    ProductFlag / implication
    AUVELITY (dextromethorphan‑bupropion)
    Listed with 'ST' indicating step therapy applies prior to coverage.
    Antidepressant(s)Formulary control
    DESVENLAFAXINE ER; FETZIMA; TRINTELLIX; FLUOXETINE DR and other antidepressants
    These agents are marked 'ST' in the formulary, indicating step therapy is required prior to coverage per plan rules.
    Antipsychotic formulationsFormulary control
    Selected antipsychotic ODT/solution formulations (e.g., aripiprazole ODT, risperidone ODT/soln)
    These formulations show 'ST' (step therapy) and QL entries in the formulary — step therapy applies prior to coverage as indicated.
    DesignationProvider requirement
    Various high‑cost/specialty products (examples: REPATHA presentations, ADEMPAS, ATTRUBY) designated SP and PA
    SP indicates specialty pharmacy routing and PA indicates prior authorization is required before benefits are provided; providers must obtain PA and comply with specialty dispensing requirements.

    Quantity Limits (QL) — Examples and Per-Product Caps

    Dispensing limits / quantity limits
    Dispensing/Quantity limits enforcementDispensing limits/quantity limits apply as noted in Special Requirements; members may be covered for a limited quantity per prescription or time period
    Claims exceeding limitsClaims above QL without authorization may be denied or the member may be responsible for full cost
    Where to verify limitsFor complete list of medications and dispensing limits, visit MyPrime.com or bcbsnm.com
    BIKTARVY example QL
    BIKTARVY exampleQL = 30 tablets/30 days
    TierListed as Drug Tier = P in formulary entry
    VerificationSee product line for Special Requirements field
    DAA QL examples
    Hepatitis C DAAs (EPCLUSA / HARVONI / MAVYRET / SOVALDI / VOSEVI)QL = 30 tablets/30 days (or as specified per product); many require PA and SP
    PA/SPEntries for these agents commonly include PA and SP designations; prior authorization required where shown
    ReferenceSee individual product lines for pack-specific QL (e.g., pellet packs may show 28-day limits)
    SUNLENCA QL
    SUNLENCA (lenacapavir)QL = 4 tablets/365 days
    FormulationsTherapy pack and single-tab listings show the same annual QL
    TierListed as Drug Tier = NP
    Linezolid / Vancomycin QLs
    Linezolid suspensionQL = 600 mls (600 mls/180 days listed)
    Linezolid 600 mg tabletsQL = 56 tablets/180 days
    Vancomycin capsulesQL = 120 capsules/30 days
    Vancomycin HCl capsules QL
    Vancomycin HCl capsulesQL = 120 capsules/30 days
    Oral solutionsFirvanq and other oral vancomycin formulations listed with separate entries and QLs
    Formulary tierEntries specify Drug Tier = NP for some formulations
    Rifaximin QLs (200 mg & 550 mg)
    Rifaximin 200 mgQL = 9 tablets/30 days
    Rifaximin 550 mgQL = 60 tablets/30 days
    Indication noteDifferent strengths have distinct QLs as listed on product lines
    Abiraterone (Zytiga) QL
    Abiraterone acetate 500 mg (Zytiga)QL = 60 tablets/30 days
    RequirementsEntry indicates PA and SP in addition to the QL
    TierListed as Drug Tier = NP
    ALUNBRIG QL examples
    ALUNBRIG (brigatinib) QLs30 tablets/30 days or 240 capsules/30 days depending on formulation
    RequirementsPA and SP apply; initiation packs have distinct 1 pack/180 days limits
    See entryRefer to specific strength/formulation line for exact QL
    BRAFTOVI QL
    BRAFTOVI (encorafenib) cap 75 mgQL = 180 capsules/30 days
    RequirementPA and SP are indicated on the product line
    TierListed as Drug Tier = NP
    Selected oncology QLs
    Mercaptopurine suspension (Purixan)QL = 180 tablets/30 days (suspension listed as 20 mg/mL)
    Neratinib 40 mgQL = 180 tablets/30 days
    Ixazomib (Ninlaro)QL = 3 capsules/28 days
    Pemigatinib & related QLs
    Pemigatinib (Pemazyre)QL = 14 tablets/21 days
    Ixazomib (Ninlaro)QL = 3 capsules/28 days
    Alpelisib (Piqray) therapy packsQL varies by pack (e.g., 28 or 56 tablets/28 days) — see product line
    Prednisolone / Rayos / Methyltestosterone QLs
    Prednisolone sodium phosphate oral solution 10 mg/5 mLQL = 900 mLs/30 days
    Rayos (prednisone delayed‑release)QL = 30 tablets/30 days
    MethyltestosteroneQL = 600 tablets/30 days
    Rayos and related steroid/androgen QLs
    Rayos (prednisone delayed‑release)QL = 30 tablets/30 days
    Methyltestosterone formulationsQL = 600 tablets/30 days (separate entry)
    Testosterone gel examplesGels: 30 packets/30 days; 2 pumps/30 days; 150 g/30 days; 300 g/30 days
    Methyltestosterone QL (summary)
    Methyltestosterone formulations (summary)QL = 600 tablets/30 days
    PA indicatedProduct lines show PA in addition to QL for methyltestosterone
    Formulation applicabilityApplies to listed oral tablet/capsule presentations
    Testosterone formulations QL examples
    Testosterone gel and other topical QLsExamples include 30 packets/30 days; 2 pumps/30 days; 150 grams/30 days; 300 grams/30 days
    Auto-injector (XYOSTED)Separate entry: QL = 2 mL/28 days
    Parenteral injectionsInjectable testosterone QLs listed per mL (e.g., 5–10 mL/28 days depending on product)
    Myfembree QL
    MyfembreeQL = 30 tablets/30 days
    RequirementsEntry indicates PA plus QL for Myfembree
    TierListed as Drug Tier = P
    Metformin, Mounjaro, Janumet QLs
    Metformin HCl oral solution (Riomet)QL = 780 mLs/30 days
    MOUNJARO (selected strengths)QL = 4 pens (examples: 4 pens/28 days or 4 pens/180 days depending on strength)
    JANUMET XRQL = 60 tablets/30 days
    MOUNJARO and insulin QLs
    MOUNJARO (selected strengths)QL = 4 pens (examples: 4 pens/28 days or 4 pens/180 days as listed)
    Rapid-acting insulins (FIASP, HUMALOG, NOVOLOG)QL = 100 mLs/30 days for many rapid-acting formulations
    Basal insulinsMultiple basal insulins listed with common QL = 100 mLs/30 days
    Insulin quantity limit
    Insulin quantity limit (common)QL = 100 mLs/30 days (applies to many insulin products)
    Products listedExamples: INSULIN GLARGINE-YFGN, SEMGLEE, TOUJEO, TRESIBA, 70/30 RELION
    VerificationSee individual insulin product lines for formulation-specific QL entries
    SOMAVERT vial QL
    SOMAVERT vialsQL = 30 vials/30 days
    RequirementsPA and SP indicated for SOMAVERT
    Product noteApplies to pegvisomant injection presentations as listed
    Selected specialty injectable QLs
    TYMLOS (abaloparatide)QL = 1.56 mLs/30 days
    TRYNGOLZA (olezarsen)QL = 1 injection device/28 days
    Various liquid formulationsExamples include QL = 1920 mLs/30 days for certain cardiovascular liquids
    Oral ACE inhibitor solution QLs
    Enalapril oral solution (Epaned)QL = 1200 mLs/30 days; PA required
    Lisinopril oral solution (QBRELIS)QL = 2400 mLs/30 days; PA required
    NoteBoth listed with PA and large-volume QLs — prior authorization required
    FUROSCIX QL
    FUROSCIX (furosemide subcutaneous cartridge kit 80 mg/10 mL)QL = 8 kits/180 days; PA required
    Specialty designationListed with SP where shown
    Coverage notePA and QL enforce coverage; refer to product line for authorization details
    Colesevelam packets QL
    Colesevelam (Welchol) packets 3.75 gmQL = 30 packets/30 days; PA required
    Tablet formsSome tablet presentations listed separately without the packet QL
    TierListed as Drug Tier = NP for packet presentations
    NEXLETOL QL
    NEXLETOL (bempedoic acid 180 mg)QL = 30 tablets/30 days; PA required
    NEXLIZET combinationAlso listed with PA and QL where applicable
    TierDrug Tier = P
    REPATHA product QLs
    REPATHA products (various presentations)QL varies by presentation (e.g., 6 syringes/28 days; 2 cartridges/30 days; 6 pens/28 days); PA required
    PushtR Nex cartridgeQL = 2 cartridges/30 days (REPATHA PUSHTRONEX)
    SureClick pensQL = 6 pens/28 days (REPATHA SURECLICK)
    UPTRAVI QL
    UPTRAVI (selexipag)QL = 60 tablets/30 days; PA and SP apply
    Titration packTitration pack listed with QL (1 pack/180 days) where shown
    TierListed as Drug Tier = P
    FASENRA PEN QL
    FASENRA PEN (benralizumab)QL = 1 pen/28 days; PA and SP apply
    TierListed as Drug Tier = P
    AdministrationPrefilled syringe/auto-injector presentations have specified QL per 28 days
    Selected biologic and CF modulator QLs
    TRIKAFTA (CF modulator)QL = 56 packets/28 days (or 90 tablets/30 days for alternate formulations); PA and SP apply
    NUCALA (mepolizumab)QL examples: 1 syringe/28 days (40 mg) or 3 mLs/28 days (100 mg/mL) with PA and SP
    SKYRIZIQL = 1 cartridge/56 days; PA and SP indicated
    Antiemetic / GI / specialty QLs
    Aprepitant (Emend) therapy packQL = 3 packs/30 days (therapy pack) or QL = 9 kits/30 days for oral suspension formulation
    AURYXIA (ferric citrate)QL = 1080 tablets/365 days
    SKYRIZI cartridgeQL = 1 cartridge/56 days
    Psychotropic medication QLs
    Aripiprazole oral solutionQL = 900 mLs/30 days
    Aripiprazole ODT/tabsQL = 60 tablets/30 days for many formulations; other strengths may have 30 or 60 tablet limits
    Clozapine ODT/tabsQL varies by strength (examples: 90, 270, 120, 180 tablets/30 days)

    Dispensing Channels and Medical Benefit Considerations

    Note
    Note
    Note
    Note
    Note
    Note

    Abbreviations and Tier Conventions

    Policy Background

    Specialty drugs are therapies used to treat complex, often chronic or rare conditions (examples include hepatitis, hemophilia, multiple sclerosis, and rheumatoid arthritis). They may be oral, topical, or injectable, and high-cost or clinically complex agents are frequently managed through additional processes such as Specialty Pharmacy (SP), site-of-care controls (for drugs administered by a health care professional), and utilization management. The drug list is maintained and updated regularly by a committee of clinicians and pharmacists, and coverage for listed products is based on FDA labeling and recognized evidence-based clinical guidelines; plan-level rules such as Prior Authorization (PA), Quantity Limits (QL), step therapy, and benefit routing determine whether a particular prescription is covered under the member's plan.

    Policy Revision History